Address
1 Corporate Drive
South San Francisco, CA 94080

Contact
contact@soley.ai

Cells Are Talkative. We Just Learned How To Listen.

Soley’s innovative evaluation platform decodes Cellular Language at scale for efficient drug discovery and development.

Our Interdisciplinary Approach

Soley Therapeutics is the brainchild of cardiologist Yerem Yeghiazarians, MD, and molecular cancer biologist Kurosh Ameri, PhD. They began working together in 2010 to answer the question “how do cells determine their fate?”

Why can cancer cells thrive under harsh conditions, while brain and heart muscle cells begin to die within minutes of exposure to low oxygen and nutrients?

All cells respond to their environment based on their internal flow of information. Soley’s powerful platform technology interprets this nuanced cellular response through a target-agnostic lens, highlighting potential drug candidates.

A New Age for Life Sciences

Soley’s groundbreaking high-throughput platform technology uses the cell as a natural sensor. It harnesses cells’ anticipatory biological capabilities, and utilizes the power of AI/ML to discover and develop drugs efficiently and effectively.

Sheila Gujrathi, M.D.

Dan Von Hoff, M.D.

Afsaneh Naimollah

Leo Grady, PhD

Fei-Fei Li, PhD

Peter Libby, MD

Keith Flaherty, MD

Clay Johnston, MD, PhD

Tony Adamis, MD

Antoine Yver, MD

Dan Von Hoff, MD

Co-Founder, CEO, Board Member